5 results about "Thymosin α1" patented technology

This invention relates to the field of biomedicine, specifically providing a mutant thymosin α1 polypeptide and its applications. The mutant differs from natural thymosin α1 by substituting at least one amino acid at positions 15, 21, and 27, with preferred mutations including D15M, E21W, and E27R. Amino acid substitutions at these sites significantly improve the structural stability and in vivo pharmacokinetic properties of thymosin α1. Experimental results show that, while maintaining the main secondary structural features and overall thermal stability without significant degradation, the mutant improves serum stability and in vivo pharmacokinetic properties, exhibiting superior in vivo half-life and antitumor activity. This invention also provides nucleic acid molecules encoding the mutant, expression vectors, host cells, and pharmaceutical compositions containing the mutant, which can be used for the treatment of tumors, viral infections, and immune-related diseases.

The present invention provides an application of recombinant chicken thymopeptide in the preparation of chicken immune enhancers, belonging to the field of veterinary technology. In the present invention, chicken thymosin α1, chicken thymosin α1 mutant and double-copy tandem protein of chicken thymosin α1 mutant are expressed by genetically engineered recombinant Escherichia coli. The action time of recombinant chicken thymopeptide in chickens is increased through two ways: mutating the positively charged amino acid K into the negatively charged amino acid D and double-copy tandem expression. Seven weeks after the injection of thymopeptide, the SI value of the chicken thymosin α1 group has dropped to 1.08, approaching the control group level, the SI value of the chicken thymosin α1 mutant group has dropped to 1.23, while the SI value of the double-copy chicken thymosin α1 mutant group still maintains a relatively high level of 1.43. It can be seen that the double-copy chicken thymosin α1 mutant has a more persistent effect on regulating the immune function of chickens than chicken thymosin α1 expressed by the natural sequence, and is a long-acting thymopeptide that can be used as an immune enhancer.

This invention belongs to the field of bioengineering technology, specifically relating to a gene for efficiently expressing thymosin α1 (Tα1), recombinant lactic acid bacteria, and their applications. This invention provides a Tα1 encoding gene specifically optimized for *Lactococcus lactis* NZ9000, which significantly improves expression efficiency in the host through full-sequence codon adaptation. This gene was cloned into the vector pNZ8148-M, constructing the recombinant expression plasmid NZ9000 / pNZ8148-M. usp45 + T α1 The strain was successfully transformed into the host bacterium NZ9000, yielding recombinant lactic acid bacteria NZ9000 / pNZ8148-M. usp45 + Tα1 This recombinant strain can efficiently secrete the Tα1 fusion protein USP under Nisin induction. 45 +Tα1, the protein is digested in vitro by enterokinase to release active Tα1. The Tα1 produced by the method of this invention has high yield, high purity, high biological activity and excellent safety, providing a new technical platform for the low-cost, large-scale and safe production of Tα1.

This invention relates to the interdisciplinary field of biomedicine and molecular imaging, specifically a novel magnetic resonance imaging contrast agent, its preparation method, and its application. The contrast agent uses thymosin α1 as the parent compound, linked with three identical substituents R, where R are metal chelate groups. These metal chelate groups are formed by coordination of a chelating agent and a metal ion; the chelating agent can be diethylenetriaminepentaacetic acid, etc., and the metal ion can be selected from gadolinium, manganese, and iron. The preparation method of the contrast agent includes: activating the chelating agent and grafting it onto thymosin α1 to form a chelate precursor; and coordinating the chelate precursor with a metal ion. The contrast agent prepared by this invention exhibits a significant T1 enhancement effect, lymphoselectivity, and reduced concomitant venous contamination; detection results show that it has excellent lymphatic system visualization capabilities in in vivo animal imaging, providing a prospective reference for replacing existing contrast agents.

The present invention belongs to the field of biomedicine, and discloses a pharmaceutical composition, its application in the preparation of a drug for treating lymphopenia, and an anti-tumor drug. The pharmaceutical composition provided by the present invention comprises thymosin α1 and recombinant human interleukin-2. Through the synergistic cooperation of thymosin α1 and recombinant human interleukin-2, it can act well on the immune system of tumor patients damaged by treatment means such as cancer cell attack, chemotherapy, cell transplantation or targeted therapy, regulate the expression balance of immune factors related to the immune system reconstruction, improve the activity of normal lymphocytes, achieve immune system reconstruction to a certain extent, promote the proliferation of lymphocytes, especially T cell subsets, relieve or treat lymphopenia caused by chemotherapy in tumor patients, and the pharmaceutical composition can also synergistically enhance the therapeutic effect of existing chemotherapy drugs, promote the clearance of cancer cells, and achieve a better anti-tumor therapeutic effect.